Market revenue in 2023 | USD 183.7 million |
Market revenue in 2030 | USD 296.7 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.32% in 2023. Horizon Databook has segmented the Japan central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, organizations such as the Japan Biological Informatics Consortium (JBIC), which are engaged in drug development, enable collaborations, and provision of services for drug research, thereby contributing to the market growth.
Many researchers are involved in collaborations with regulatory authorities to discover and validate surrogate markers for use in drug development. The Japanese government and regulatory authorities have implemented a framework to encourage such collaborations and partnerships.
This is expected to create enhanced opportunities for undertaking clinical trials for novel drug candidates. The proportion of the geriatric population is increasing rapidly in Japan, wherein both life expectancy & per capita income among the population aged 80 and above are high.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan central lab market , including forecasts for subscribers. This country databook contains high-level insights into Japan central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account